Pim-1 kinase as cancer drug target: An update (Review)
作者： YERNAR TURSYNBAY , JINFU ZHANG , ZHI LI , TURSONJAN TOKAY , ZHAXYBAY ZHUMADILOV
DOI: 10.3892/BR.2015.561
关键词:
摘要: Proviral integration site for Moloney murine leukemia virus-1 (Pim-1) is a serine/threonine kinase that regulates multiple cellular functions such as cell cycle, survival, drug resistance. Aberrant elevation of Pim-1 associated with numerous types cancer. Two distinct isoforms (Pim-1S and Pim-1L) show functions. Pim-1S predominately localizes to the nucleus Pim-1L plasma membrane Recent studies mitochondrial maintains integrity. emerging cancer target, particularly in prostate Recently potent new immunotherapy, senescence bypass, metastasis epigenetic dynamics have been found. The aim present updated review provide brief information regarding networks focus on its recent advances novel target.
nu.edu.kz参考文章(69)
Tianyun Jiang, Zhiyong Guo, Bojie Dai, Miyoung Kang, David K. Ann, Hsing-Jien Kung, Yun Qiu, Bi-directional Regulation between Tyrosine Kinase Etk/BMX and Tumor Suppressor p53 in Response to DNA Damage Journal of Biological Chemistry. ,vol. 279, pp. 50181- 50189 ,(2004) , 10.1074/JBC.M409108200
Karthika Natarajan, Yingqiu Xie, Mehmet Burcu, Douglas E. Linn, Yun Qiu, Maria R. Baer, Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication PLoS ONE. ,vol. 8, pp. e74653- ,(2013) , 10.1371/JOURNAL.PONE.0074653
Bo Jin, Yu Wang, Chen Lin Wu, Kai Yu Liu, Hao Chen, Ze Bin Mao, PIM-1 modulates cellular senescence and links IL-6 signaling to heterochromatin formation. Aging Cell. ,vol. 13, pp. 879- 889 ,(2014) , 10.1111/ACEL.12249
Y Xie, K Xu, B Dai, Z Guo, T Jiang, H Chen, Y Qiu, The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. ,vol. 25, pp. 70- 78 ,(2006) , 10.1038/SJ.ONC.1209058
Carmen Blanco-Aparicio, Ana María García Collazo, Julen Oyarzabal, Juan F. Leal, María Isabel Albarán, Francisco Ramos Lima, Belén Pequeño, Nuria Ajenjo, Mercedes Becerra, Patricia Alfonso, María Isabel Reymundo, Irene Palacios, Genoveva Mateos, Helena Quiñones, Ana Corrionero, Amancio Carnero, Paolo Pevarello, Ana Rodríguez Lopez, Jesús Fominaya, Joaquín Pastor, James R. Bischoff, Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition Cancer Letters. ,vol. 300, pp. 145- 153 ,(2011) , 10.1016/J.CANLET.2010.09.016
Jaspal Kaur Kumar, Ryan Yueh Shyang Ping, Huey Fern Teong, Shijie Goh, Marie-Véronique Clément, Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells. The International Journal of Biochemistry & Cell Biology. ,vol. 43, pp. 594- 603 ,(2011) , 10.1016/J.BIOCEL.2010.12.017
Marie-Anne Hospital, Alexa S. Green, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Jerome Tamburini, The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood. ,vol. 119, pp. 1791- 1792 ,(2012) , 10.1182/BLOOD-2011-11-393066
Chiara Riganti, Elena Gazzano, Giulia Rossana Gulino, Marco Volante, Dario Ghigo, Joanna Kopecka, Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Letters. ,vol. 360, pp. 219- 226 ,(2015) , 10.1016/J.CANLET.2015.02.008
CHEN LIANG, YING-YI LI, Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review) Molecular Medicine Reports. ,vol. 9, pp. 2051- 2060 ,(2014) , 10.3892/MMR.2014.2139
Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Mehmet Burcu, Zhe-Sheng Chen, Suresh V. Ambudkar, Maria R. Baer, The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms Biochemical Pharmacology. ,vol. 85, pp. 514- 524 ,(2013) , 10.1016/J.BCP.2012.12.006